Merck's Keytruda Secures FDA Nod For Head And Neck Cancer As First Immunotherapy For Use Around Surgery

Why did oil prices surge after Israel attacked Iran? How will the Nippon Steel and US Steel merger impact markets? What delayed Tesla's robotaxi launch and stock effect? How are Israel-Iran strikes affecting global stock markets? Why are Walmart and Amazon exploring stablecoin issuance? What caused the recent drop in consumer sentiment? How is AI reshaping hiring at Chipotle and other firms?

Merck's Keytruda Secures FDA Nod For Head And Neck Cancer As First Immunotherapy For Use Around Surgery

benzinga.com/news/fda/25/06/45932581/mercks-keytruda-secures-fda-nod-for-head-and-neck-cancer-as-first-immunotherapy-for-use-around-surgery

The U.S. Food and Drug Administration (FDA) on Friday approved Merck & Co Inc.’s (NYSE:MRK) Keytruda (pembrolizumab) for adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 (combined positive score of at least 1), as a…

This story appeared on benzinga.com, 2025-06-13 18:08:45.